119
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      scite_
       
      • Record: found
      • Abstract: found
      • Conference Proceedings: found
      Is Open Access

      REPO4EU, REPOSystem and Applicable Bioinformatics : REPO-HFpEF and CIPER

      Published
      conference-abstract
        1 ,
      RExPO24 Conference
      REPO4EU
      RExPO24
      3-5 July 2024
      Drug Repurposing, Precision Medicine, Bioinformatics, Protein-Protein Interaction, Network Pharmacology, Diagnostics, Clinical Trials, Phase II, ERIC, ESFRI
      Bookmark

            Abstract

            REPO4EU is an EU-funded initiative focused on drug repurposing, uniting 28 partners from 10 countries to create a comprehensive platform for mechanism-based drug repurposing. This initiative aims to advance precision medicine and reduce costs and development time. The platform emphasizes bioinformatics, 1precision diagnostics, 2and innovative clinical trials to redefine disease treatment and improve patient outcomes. Drug repurposing offers advantages such as low costs and rapid patient benefits but faces high failure rates due to limited resources among small companies and academic groups. To mitigate this risk, REPO4EU combines drug repurposing with a novel disease approach, constructing protein-protein interaction or signaling modules 3derived from disease-associated genes. Therapeutically, network pharmacology 4targets multiple proteins within a module to preempt feedback mechanisms that may reduce single-drug efficacy. Diagnostics are crucial for applying this therapeutic approach to patients sharing the same causal mechanism. These theranostic pairs are validated in phase IIa proof-of-concept trials. Over its seven-year duration, REPO4EU aims to establish a permanent European infrastructure named REPOSystem, synergistic with existing health-related infrastructures like BBMRI-ERIC, eu-openscreen, and INFRAFRONTIER, all sharing the goal of precision medicine. This approach has been validated in two cardiovascular and one cancer indication.

            Content

            Author and article information

            Conference
            RExPO24 Conference
            REPO4EU
            12 June 2024
            Affiliations
            [1 ] Maastricht University, Maastricht, Limburg, Netherlands ( https://ror.org/02jz4aj89)
            Author notes
            Author information
            https://orcid.org/0000-0003-0419-5549
            Article
            10.58647/REXPO.24000071.v1
            eee801a1-9bd4-45e9-8900-2703f89d1693

            This work has been published open access under Creative Commons Attribution License CC BY 4.0 , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Conditions, terms of use and publishing policy can be found at www.scienceopen.com .

            RExPO24
            3
            Munich, Germany
            3-5 July 2024
            History
            : 12 June 2024
            Product

            REPO4EU

            Funding
            Funded by: funder-id http://dx.doi.org/10.13039/100018696, HORIZON EUROPE Health;
            Award ID: 101057619
            Categories

            The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
            Pharmacology & Pharmaceutical medicine
            Drug Repurposing,Precision Medicine,Bioinformatics,Protein-Protein Interaction,Network Pharmacology,Diagnostics,Clinical Trials,Phase II,ERIC,ESFRI

            Comments

            Comment on this article